Chronic kidney disease (CKD)
When treating anemia in CKD patients not on dialysis
divider
Expected rise in hemoglobin (Hb) starting
at Week 41,2*
Expected rise in hemoglobin (Hb) starting at Week 4
Study design
Based on a prospective, interventional study in 56 patients not on dialysis receiving initiation doses of 50 U/kg to 100 U/kg TIW. Mean change in Hb values based on 50 U/kg and 100 U/kg; does not include 150 U/kg dosing.1,3

  • Results demonstrated a >1.0 g/dL mean increase in Hb in 4 weeks and a >2.0 g/dL mean increase in 8 weeks1,3
  • These Hb increases were calculated from the hematocrit (HCT) increases, assuming an HCT:Hb conversion rate of 3:14
*Week 4: 50 U/kg (n=27); 100 U/kg (n=25).3
 Week 8: 50 U/kg (n=27); 100 U/kg (n=24).3
divider
Selected safety profile
Adverse reactions occurring in ≥5% of adult patients5†

Adverse reaction PROCRIT®-treated patients (n=131) Placebo-treated patients (n=79)
Hypertension 13.7% 10.1%
Arthralgia 12.2% 7.6%
  • From 2 double-blind, placebo-controlled studies in 210 patients with CKD not on dialysis5
†Adverse reactions with a reported incidence of ≥5% in patients treated with PROCRIT® that occurred at ≥1% higher frequency than in placebo-treated patients.5
divider

References
  1. The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis. 1991;18:50-59.
  2. Abels R. Rate of progression of chronic renal failure in predialysis patients treated with erythropoietin. Semin Nephrol. 1990;10(suppl 1):20-25.
  3. Data on file. Janssen Products, LP.
  4. Kawthalkar SM. Essentials of Haematology. 2nd ed. New Delhi, India: Jaypee Brothers Medical Publishers (P) Ltd; 2013.
  5. PROCRIT® (epoetin alfa) Prescribing Information. Janssen Products, LP.
 
Indications and Important Safety Information
EXPAND    Expand ISI
Indications
Expand ISI
Important Safety Information
Expand ISI